NCT00022581View on ClinicalTrials.gov

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

December 31, 2004

Conditions
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Small Lymphocytic Lymphoma
Interventions
DRUG

thalidomide

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60604-1104

Cancer and Leukemia Group B (CALGB) Research Base, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00022581 - Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter